Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Nektar Therapeutics

2018 · Licensing/Option · $3.6B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Did not work — the deal failed to deliver.

Bristol-Myers Squibb entered a global clinical collaboration with Nektar Therapeutics to evaluate combinations of BMS's immuno-oncology portfolio (including Opdivo and Yervoy) with Nektar's NKTR-214 (bempegaldesleukin), a CD122-biased IL-2 pathway agonist. BMS paid $1.85B upfront ($1B cash + $850M equity investment) with up to $1.78B in additional milestone payments.

Key facts

Announced Feb 14, 2018
Closed Apr 03, 2018
Deal value $3.6B
Deal type Licensing/Option
Therapeutic area Oncology
Indications Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bladder Cancer, Multiple Solid Tumors
Key assets NKTR-214 (bempegaldesleukin)
Mechanism CD122-biased IL-2 pathway agonist, PEGylated IL-2 cytokine

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals